Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, ... ( WOODCLIFF LAKE N.J. May 5 /- Eisa...)

Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.

Date:5/5/2008

WOODCLIFF LAKE, N.J., May 5 /PRNewswire/ -- Eisai Corporation of North America today announces the immediate appointment of Cynthia Schwalm as President of Eisai Inc. In her new role, Ms. Schwalm will have full operating responsibility for leading Eisai Inc., the U.S. commercial operation of Eisai Co., Ltd.

Ms. Schwalm brings to Eisai Inc. a strong track record of building high-performing organizations that drive global growth and nearly 25 years of senior healthcare experience in the fields of pharmaceuticals, biotechnology and medical devices. She will report to Lonnel Coats, President & COO, Eisai Corporation of North America. Previously, Mr. Coats held dual responsibilities, also serving as President & COO of Eisai Inc.

"Ms. Schwalm is an exciting addition to our company. She will be instrumental in driving Eisai's integration of MGI PHARMA and strengthening our presence in the U.S. as a top-20 pharmaceutical company," said Mr. Coats. "Ms. Schwalm has an extensive background in oncology, neurology, critical care and gastroenterology, areas of therapeutic focus for Eisai. She will be invaluable to our future growth, as we continue to advance our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families."

Ms. Schwalm joins Eisai from Amgen, Inc., where over the course of her five-year tenure she rose to Vice President and General Manager of the U.S. Oncology Business Unit, a group with annual revenues exceeding $5 billion. In this role she led the 500-person business unit, oversaw all oncology strategy and served as a member of Amgen's Senior Management Team responsible for talent development in medical affairs, drug development, regulatory, and health economic functions.

Prior to Amgen, Inc., Ms. Schwalm grew her pharmaceutical career over an 18-year period within Johnson & Johnson (J&J), holding positions of increasing responsibility at various J&J companies. During this
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
2. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
3. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
4. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
5. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
6. BioElectronics Corporation Receives Major Orders From Italian Distributor
7. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
8. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
9. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
10. Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date
11. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers

Post Your Comments:

Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, ...( WOODCLIFF LAKE N.J. May 5 /- Eisa...)